J&J Innovative Medicine
What’s the difference between a heart attack and cardiac arrest?
Both are life-threatening heart-health emergencies, but they are two distinct conditions with different causes and treatment. Here’s what a cardiologist wants you to know.
Meet two brothers who are revolutionizing the way scientists develop treatments for cancer
Justin and Colin Farlow share how their next-generation cell and gene therapies are helping Johnson & Johnson in its quest to get in front of cancer.
Getting in front of cancer
Every year, roughly 2 million people in the U.S. are newly diagnosed with cancer. But a number of scientific breakthroughs—including ones made at Johnson & Johnson—have dramatically changed what kind of prognosis many of these patients will have.
What is a gene mutation?
Experts aren’t sure why, but sometimes changes in DNA can trigger cancer to grow and spread. For DNA Day learn all about gene mutations—and Johnson & Johnson’s work developing new therapies to target these specific types of cancer.
What you need to know about Johnson & Johnson’s 2024 first-quarter earnings
Here’s an infographic breakdown of the company’s first-quarter earnings results, including key highlights from its Innovative Medicine and MedTech businesses.
What is an orphan drug?
The need for these rare disease therapies is strong, and access to them can be lifesaving. Here’s how Johnson & Johnson is innovating to help give patients options.
Biomedical scientist Robert Langer receives the 2023 Dr. Paul Janssen Award for Biomedical Research
Each year, Johnson & Johnson honors a scientist currently working in academia, industry or a scientific institute who has made a significant contribution toward the improvement of public health.
Johnson & Johnson named a 2024 Fortune World’s Most Admired Company
The company makes the list for the 22nd year in a row, thanks to its dedication to innovation, social responsibility and more.
Is this the end of one-size-fits-all treatments for depression?
Learn how Johnson & Johnson is working to bring personalized psychiatry to the 7 in 10 people with depression whose treatments aren’t getting the job done.